Fortress Biotech Inc. (NASDAQ:FBIO) SVP George Avgerinos sold 48,912 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $2.55, for a total value of $124,725.60. Following the completion of the sale, the senior vice president now owns 293,000 shares of the company’s stock, valued at approximately $747,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fortress Biotech Inc. (NASDAQ:FBIO) opened at 2.62 on Tuesday. Fortress Biotech Inc. has a 12-month low of $2.10 and a 12-month high of $4.66. The stock has a 50 day moving average price of $2.76 and a 200-day moving average price of $2.98. The firm’s market cap is $127.51 million.

Fortress Biotech (NASDAQ:FBIO) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.02. Fortress Biotech had a negative net margin of 1,687.06% and a negative return on equity of 79.62%. Equities analysts forecast that Fortress Biotech Inc. will post ($1.03) earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Fortress Biotech by 7.3% in the second quarter. Vanguard Group Inc. now owns 1,345,439 shares of the biopharmaceutical company’s stock worth $3,619,000 after buying an additional 91,242 shares during the period. BlackRock Fund Advisors raised its stake in shares of Fortress Biotech by 999.1% in the second quarter. BlackRock Fund Advisors now owns 893,101 shares of the biopharmaceutical company’s stock worth $2,402,000 after buying an additional 811,844 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in shares of Fortress Biotech by 129.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 314,920 shares of the biopharmaceutical company’s stock worth $847,000 after buying an additional 177,930 shares during the period. State Street Corp raised its stake in shares of Fortress Biotech by 2,170.8% in the second quarter. State Street Corp now owns 268,632 shares of the biopharmaceutical company’s stock worth $723,000 after buying an additional 256,802 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Fortress Biotech by 125.8% in the second quarter. Bank of New York Mellon Corp now owns 148,103 shares of the biopharmaceutical company’s stock worth $398,000 after buying an additional 82,525 shares during the period. Institutional investors and hedge funds own 16.67% of the company’s stock.

Separately, FBR & Co reissued an “outperform” rating on shares of Fortress Biotech in a report on Wednesday, July 20th.

About Fortress Biotech

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

5 Day Chart for NASDAQ:FBIO

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.